Trapping of adrenergic decongestant drugs into cellular endomembrane compartments: toxicological and pharmacological consequences.
Rhinitis of allergic and viral origin is often self-treated by patients with locally applied vasoconstrictor decongestant drugs. In turn, prolonged use of these agents produce an inflammatory condition termed rhinitis medicamentosa. Cationic drugs are sequestered into cells via various mechanisms, including mitochondrial concentration and V-ATPase-driven trapping in vacuoles that swell by an osmotic mechanism. We hypothesized that receptor-independent endomembrane sequestration of topically applied concentrated alpha-adrenoceptor agonists (decongestants, mydriatics) could contribute to their toxicity and prolonged duration of action. The morphological and functional effects of phenylephrine and xylometazoline on rabbit aortic smooth muscle cells were examined and their possible sequestration evaluated using the contractility of rabbit aorta rings. Synthetic agonists produced V-ATPase-dependent cell vacuolization (prevented by bafilomycin A1; xylometazoline 250 microM, phenylephrine 2.5 mM). V-ATPase-mediated cytotoxicity was slow (24 h; phenylephrine only, 5-10 mM); a rapid xylometazoline-induced cytotoxicity (> or =500 microM, 4 h) correlated to mitochondrial functional alterations. Xylometazoline had slower contraction and relaxation kinetics than the other alpha-adrenoceptor agonists in the aorta; bafilomycin pre-treatment influenced its kinetics (accelerated contraction and relaxation) and concentration-effect relationship (potentiation). V-ATPase-driven sequestration contributed to a component of the tissue reservoir of both phenylephrine and xylometazoline as assessed by aortic rings contracted with the concentrated agonists and subsequently washed. Phenylephrine and xylometazoline caused the V-ATPase-dependent cytopathology at a fraction of the usual topical concentrations; this form of sequestration influenced the toxicity and pharmacology of individual agents.
Centre de recherche en Rhumatologie et Immunologie, Centre Hospitalier Universitaire de Québec, Québec Qc, Canada G1V 4G2.
Guillaume
G
Morissette
Johanne
J
Bouthillier
François
F
Marceau
D000316:Adrenergic alpha-Agonists / Q000633:toxicity; D000818:Animals; D001011:Aorta / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D004837:Epinephrine / Q000633:toxicity; D007093:Imidazoles / Q000633:toxicity; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism*; D014663:Nasal Decongestants / Q000633:toxicity*; D010656:Phenylephrine / Q000633:toxicity; D011817:Rabbits; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects* / Q000378:metabolism; D025262:Vacuolar Proton-Translocating ATPases / Q000187:drug effects* / Q000378:metabolism*; D014617:Vacuoles / Q000187:drug effects / Q000378:metabolism*; D014662:Vasoconstrictor Agents / Q000633:toxicity
D000316:Adrenergic alpha-Agonists; D007093:Imidazoles; D014663:Nasal Decongestants; D011942:Receptors, Adrenergic, alpha; D014662:Vasoconstrictor Agents; D010656:Phenylephrine; D025262:Vacuolar Proton-Translocating ATPases; C009695:xylometazoline; D004837:Epinephrine